The COVID-19 pandemic threatens to reverse recent progress in reducing the global burden of tuberculosis. The global number of deaths for tuberculosis could increase by around 200.000–400.000 in 2020 alone, as result of essential tuberculosis services disruptions due to the reallocation of human, financial and other resources from tuberculosis to the COVID-19 response, as reported by WHO: https://bit.ly/35KyzD
In a Controlled Human Infection Model (CHIM) study, a well-characterised strain of an infectious agent is given to carefully selected adult volunteers in order to better understand human diseases, how they spread, and
Ebola vaccine candidates are currently being evaluated in phase I–III clinical trials conducted in Africa, the EU and the US. Although preclinical development of candidate vaccines utilise different platforms, including
In this article published by Nature, Prof. Francine Ntoumi addresses how the efforts to tackle Covid-19 are consequently and tragically neglecting all other diseases, for which it is estimated that